Pharmaceutical Parallel Trade in the UK

Panos Kanavos
Paul Holmes

Commentaries by
David Loudon
Sue Mitchell
David Taylor
Jim Thomson

Benedict Irvine (editor)
Contents

Authors vi
Foreword vii

PART I: Pharmaceutical Parallel Trade in the UK
Panos Kanavos and Paul Holmes

Executive Summary 3

1. Introduction 7

2. Legislative Background
   2.1. Parallel Trade and the EU Treaties
   2.2. Issues arising from the ECJ jurisprudence
   2.3. Conclusion

3. Regulatory Issues
   3.1 Parallel distribution notification (centralised procedure)
   3.2 Parallel distribution notification (de-centralised procedure)
   3.3 Regulatory shortcomings
   3.4. Concluding remarks on regulatory issues

4. Institutional Policies Encouraging the use of PI Medicines
   4.1 Institutional policies encouraging the dispensing of parallel-imported pharmaceuticals
   4.2 Policies indirectly encouraging (or discouraging) PI
   4.3 The impact of PI on patient access to medicines
   4.4 Policy lessons and conclusions

5. UK Market Structure 31

6. The Economic Impact of Parallel Trade 42
   6.1 Background
   6.2 Methodological issues
   6.3 Economic impact

7. Overall Conclusions and Summary 49
   7.1 Legislative issues
   7.2 Regulatory issues
   7.3 Institutional issues
   7.4 Market structure issues
   7.5 Economic impact

PART II: Patient Safety Issues and Proposals for Reform

1. Editor’s Introduction 55

2. Stakeholder Views on Parallel Trade
   The Patient Perspective from Epilepsy Action
      Sue Mitchell 56
   Parallel Trade from a Dispensing Chemist’s Perspective
      David Loudon 60
   Parallel Trade from a Patient Organisation Perspective
      Jim Thomson 62
   Private Concerns and Public Interests
      David Taylor 63

3. Evidence of Patient Safety Concerns 67

4. Proposals for Reform 71

5. Conclusion 79

Appendix 1 81
Notes 82